Alzex Neuropharma Inc. (TRRI)

Alzex Neuropharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2011	FY 2010	FY 2009	FY 2008	FY 2007
Period Ending	Dec 31, 2011	Dec 31, 2010	Dec 31, 2009	Dec 31, 2008	Dec 31, 2007
Cash & Equivalents	0.11	0.05	0	0.05	0.1
Short-Term Investments	-	-	-	-	0
Cash & Short-Term Investments	0.11	0.05	0	0.05	0.1
Cash Growth	108.46%	1145.78%	-90.88%	-53.14%	-31.23%
Accounts Receivable	0.17	0.35	0.38	0.49	0.65
Receivables	0.17	0.35	0.38	0.49	0.68
Other Current Assets	0.01	0.02	0	0.02	0.01
Total Current Assets	0.29	0.42	0.38	0.56	0.8
Property, Plant & Equipment	0	0.01	0.02	0.03	0.02
Goodwill	1.35	1.35	1.35	1	1.35
Other Intangible Assets	0.25	0.3	0.36	0.43	0.06
Other Long-Term Assets	-	0.23	0.06	0.07	-
Total Assets	1.9	2.31	2.18	2.09	2.22
Accounts Payable	0.08	0.08	0.11	0.02	0.01
Accrued Expenses	0.11	0.12	0	0.14	0.34
Other Current Liabilities	0.02	0.01	0.03	0.21	-
Total Current Liabilities	0.2	0.22	0.14	0.37	0.35
Long-Term Debt	0.62	0.84	1.32	1.39	1.92
Other Long-Term Liabilities	0.03	0.05	0.09	-	-
Total Liabilities	0.85	1.11	1.56	1.76	2.27
Common Stock	0.71	1.2	0.25	0.09	0.02
Additional Paid-In Capital	0.03	-	0.09	0.94	0.04
Retained Earnings	-0.09	-	-0.2	-	-0.16
Comprehensive Income & Other	0.39	-	0.46	-0.71	-
Total Common Equity	1.05	1.2	0.61	0.32	-0.1
Shareholders' Equity	1.05	1.2	0.62	0.33	-0.05
Total Liabilities & Equity	1.9	2.31	2.18	2.09	2.22
Total Debt	0.62	0.84	1.32	1.39	1.92
Net Cash (Debt)	-0.51	-0.78	-1.32	-1.34	-1.82
Working Capital	0.09	0.2	0.24	0.19	0.45
Tangible Book Value	-0.56	-0.45	-1.1	-1.11	-1.51

Source: S&P Global Market Intelligence. Standard template. Financial Sources.